Geoffrey R. Oxnard - Publications

Germline determinants of risk and molecular subtype in young-onset lung cancer.

Journal: medRxiv : the preprint server for health sciences

Published: July 17, 2026

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.

Journal: The Lancet. Respiratory medicine

Published: February 06, 2026

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 15, 2025

Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 13, 2025

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 25, 2025

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Journal: Nature communications

Published: July 28, 2025

EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy.

Journal: JCI insight

Published: June 30, 2025

Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.

Journal: JCO precision oncology

Published: April 10, 2025

Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.

Journal: The Journal of molecular diagnostics : JMD

Published: April 09, 2025

Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 21, 2025

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 08, 2025

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.

Journal: Journal for immunotherapy of cancer

Published: November 26, 2024